BioInvent International AB (publ) (BINV.ST)
SEK 28.2
(1.26%)
SEK 28.2
(1.26%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 11.84 Million SEK | 2.94% |
| 2022 | 11.5 Million SEK | -31.71% |
| 2021 | 16.84 Million SEK | 313.04% |
| 2020 | 4.07 Million SEK | -24.18% |
| 2019 | 5.38 Million SEK | 82.37% |
| 2018 | 2.95 Million SEK | 23.64% |
| 2017 | 2.38 Million SEK | 24.4% |
| 2016 | 1.91 Million SEK | 313.36% |
| 2015 | 464 Thousand SEK | 660.66% |
| 2014 | 61 Thousand SEK | -70.24% |
| 2013 | 205 Thousand SEK | -17.67% |
| 2012 | 249 Thousand SEK | -11.7% |
| 2011 | 282 Thousand SEK | -58.71% |
| 2010 | 683 Thousand SEK | -66.47% |
| 2009 | 2.03 Million SEK | -11.59% |
| 2008 | 2.3 Million SEK | -39.76% |
| 2007 | 3.82 Million SEK | -50.89% |
| 2006 | 7.78 Million SEK | 163.23% |
| 2005 | 2.95 Million SEK | -48.57% |
| 2004 | 5.75 Million SEK | -41.87% |
| 2003 | 9.89 Million SEK | -27.74% |
| 2002 | 13.69 Million SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 10.51 Million SEK | 17.15% |
| 2024 Q1 | 8.97 Million SEK | -24.21% |
| 2024 Q3 | 9.89 Million SEK | -5.93% |
| 2023 Q4 | 11.84 Million SEK | -11.05% |
| 2023 Q3 | 13.31 Million SEK | 23.81% |
| 2023 FY | 11.84 Million SEK | 2.94% |
| 2023 Q2 | 10.75 Million SEK | -23.82% |
| 2023 Q1 | 14.11 Million SEK | 22.69% |
| 2022 Q1 | 13.48 Million SEK | -19.96% |
| 2022 Q3 | 11.23 Million SEK | -7.69% |
| 2022 Q4 | 11.5 Million SEK | 2.38% |
| 2022 FY | 11.5 Million SEK | -31.71% |
| 2022 Q2 | 12.17 Million SEK | -9.72% |
| 2021 Q4 | 16.84 Million SEK | 28.33% |
| 2021 FY | 16.84 Million SEK | 313.04% |
| 2021 Q1 | 6.89 Million SEK | 68.94% |
| 2021 Q3 | 13.12 Million SEK | 5.43% |
| 2021 Q2 | 12.45 Million SEK | 80.71% |
| 2020 Q1 | 5.81 Million SEK | 8.07% |
| 2020 FY | 4.07 Million SEK | -24.18% |
| 2020 Q4 | 4.07 Million SEK | -3.02% |
| 2020 Q3 | 4.2 Million SEK | -24.53% |
| 2020 Q2 | 5.57 Million SEK | -4.15% |
| 2019 Q3 | 10.79 Million SEK | 85.07% |
| 2019 Q4 | 5.38 Million SEK | -50.15% |
| 2019 FY | 5.38 Million SEK | 82.37% |
| 2019 Q1 | 2.83 Million SEK | -3.86% |
| 2019 Q2 | 5.83 Million SEK | 105.64% |
| 2018 Q1 | 2.33 Million SEK | -2.14% |
| 2018 FY | 2.95 Million SEK | 23.64% |
| 2018 Q2 | 2.7 Million SEK | 15.76% |
| 2018 Q4 | 2.95 Million SEK | 39.94% |
| 2018 Q3 | 2.1 Million SEK | -22.01% |
| 2017 Q4 | 2.38 Million SEK | -48.42% |
| 2017 FY | 2.38 Million SEK | 24.4% |
| 2017 Q1 | 225 Thousand SEK | -88.27% |
| 2017 Q2 | 2.28 Million SEK | 915.56% |
| 2017 Q3 | 4.62 Million SEK | 102.45% |
| 2016 FY | 1.91 Million SEK | 313.36% |
| 2016 Q3 | 1.28 Million SEK | 1543.59% |
| 2016 Q2 | 78 Thousand SEK | -96.44% |
| 2016 Q1 | 2.18 Million SEK | 371.55% |
| 2016 Q4 | 1.91 Million SEK | 49.61% |
| 2015 Q1 | 86 Thousand SEK | 40.98% |
| 2015 Q4 | 464 Thousand SEK | -84.06% |
| 2015 Q3 | 2.91 Million SEK | -9.65% |
| 2015 Q2 | 3.22 Million SEK | 3646.51% |
| 2015 FY | 464 Thousand SEK | 660.66% |
| 2014 Q4 | 61 Thousand SEK | -41.9% |
| 2014 FY | 61 Thousand SEK | -70.24% |
| 2014 Q3 | 105 Thousand SEK | 32.91% |
| 2014 Q2 | 79 Thousand SEK | -55.37% |
| 2014 Q1 | 177 Thousand SEK | -13.66% |
| 2013 FY | 205 Thousand SEK | -17.67% |
| 2013 Q2 | 124 Thousand SEK | 0.81% |
| 2013 Q3 | 268 Thousand SEK | 116.13% |
| 2013 Q1 | 123 Thousand SEK | -50.6% |
| 2013 Q4 | 205 Thousand SEK | -23.51% |
| 2012 FY | 249 Thousand SEK | -11.7% |
| 2012 Q1 | 252 Thousand SEK | -10.64% |
| 2012 Q2 | 217 Thousand SEK | -13.89% |
| 2012 Q3 | 217 Thousand SEK | 0.0% |
| 2012 Q4 | 249 Thousand SEK | 14.75% |
| 2011 Q1 | 895 Thousand SEK | 31.04% |
| 2011 Q2 | 422 Thousand SEK | -52.85% |
| 2011 Q3 | 328 Thousand SEK | -22.27% |
| 2011 Q4 | 282 Thousand SEK | -14.02% |
| 2011 FY | 282 Thousand SEK | -58.71% |
| 2010 Q1 | 1.15 Million SEK | -43.2% |
| 2010 FY | 683 Thousand SEK | -66.47% |
| 2010 Q3 | 1.97 Million SEK | -33.11% |
| 2010 Q2 | 2.94 Million SEK | 154.8% |
| 2010 Q4 | 683 Thousand SEK | -65.37% |
| 2009 Q4 | 2.03 Million SEK | 0.0% |
| 2009 FY | 2.03 Million SEK | -11.59% |
| 2008 FY | 2.3 Million SEK | -39.76% |
| 2007 FY | 3.82 Million SEK | -50.89% |
| 2006 FY | 7.78 Million SEK | 163.23% |
| 2005 FY | 2.95 Million SEK | -48.57% |
| 2004 FY | 5.75 Million SEK | -41.87% |
| 2003 FY | 9.89 Million SEK | -27.74% |
| 2002 FY | 13.69 Million SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AcouSort AB (publ) | 2.08 Million SEK | -469.423% |
| Active Biotech AB (publ) | -2500.00 SEK | 473860.0% |
| Alzinova AB (publ) | -3.27 Million SEK | 461.318% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Alligator Bioscience AB (publ) | 2.00 SEK | -592199900.0% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 42.021% |
| Camurus AB (publ) | 100.95 Million SEK | 88.268% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | -193.604% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 50.753% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 797139.031% |
| Kancera AB (publ) | -1950.00 SEK | 607484.615% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | - SEK | -Infinity% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 828.413% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 66.38% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 545.23 Thousand SEK | -2072.266% |
| Saniona AB (publ) | 1.00 SEK | -1184399900.0% |
| Simris Alg AB (publ) | 1.09 Million SEK | -985.61% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 2749.747% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 88.916% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 72.947% |
| Amniotics AB (publ) | 534 Thousand SEK | -2117.978% |
| CombiGene AB (publ) | -1.79 Million SEK | 758.366% |
| Genovis AB (publ.) | 14.9 Million SEK | 20.537% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 1472.423% |
| Xintela AB (publ) | 398 Thousand SEK | -2875.879% |
| Ziccum AB (publ) | -4.18 Million SEK | 382.741% |
| Intervacc AB (publ) | 10.48 Million SEK | -12.983% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 265.975% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Corline Biomedical AB | -3.85 Million SEK | 407.078% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -1184300.0% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | -30.613% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | -276.0% |
| Biovica International AB (publ) | 2.19 Million SEK | -438.608% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -1184399900.0% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | -1592.0% |
| 2cureX AB (publ) | -1000.00 SEK | 1184500.0% |
| I-Tech AB | 4.28 Million SEK | -176.729% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | -20.956% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Biosergen AB | -4.92 Million SEK | 340.292% |
| Nanologica AB (publ) | 2.97 Million SEK | -298.385% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 3788.054% |
| Oncopeptides AB (publ) | 2.42 Million SEK | -388.412% |
| Pila Pharma AB (publ) | 1.00 SEK | -1184399900.0% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | -1052.14% |